Top Markets
Coin of the day
RayzeBio, Inc. Common Stock RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZB
Rank in Stocks #5675
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs)... RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
Share Price
$62.49
Last synced: 2024-03-06
Market Cap
$2.52B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade RayzeBio, Inc. Common Stock (RYZB)

Category

Stock price history for RayzeBio, Inc. Common Stock (RYZB)
Highest end of day price: $62.49 on 2024-03-01

Lowest end of day price: $20.99 on 2023-09-01
Stock price history of RayzeBio, Inc. Common Stock from 2023 to 2026
Annual Stock Price Performance
Year Performance
2024 87.31%
2023 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.63 -12.65%
AU
$762.91 6.87%
CH